On February 12, Shanghai Yizhong and BAHEAL Pharmaceutical signed a cooperation agreement in Qingdao, and the two sides will cooperate on the commercialization of Shanghai Yizhong's innovative tumor drug "Paclitaxel Polymer Micelle for Injection" (hereinafter referred to as "paclitaxel Micelle") zisheng, jointly promoting the accessibility of domestic tumor innovative drugs and benefiting many cancer patients in China.
It is reported that as the cornerstone drug of anti-tumor chemotherapy, paclitaxel products have a wide range of indications, accurate efficacy and large clinical needs, and are currently one of the most widely used anti-tumor chemotherapy star drugs in China, and have been developing for 30 years. The "paclitaxel polymer micelle for injection" Zisheng independently developed by Shanghai Yizhong is the latest dosage form of class 2.2 third-generation paclitaxel approved by the State Food and Drug Administration (NMPA) (an innovative dosage form that has not been listed at home and abroad), and it is also the first paclitaxel micelle approved for marketing in China, and its phase III clinical research is the first batch of projects approved by the national "major new drug creation" science and technology major special project "13th Five-Year Plan". Compared with other paclitaxel dosage forms on the market, paclitaxel micelles have relatively better safety in the case of significant increases in clinical doses; clinical trial results for non-small cell lung cancer (NSCLC) show that the objective response rate (ORR) of paclitaxel micelles is significantly improved, the progression-free survival (PFS) is significantly prolonged, and the efficacy and safety of the first-line treatment of advanced non-small cell lung cancer have shown their unique advantages and advancedness, which will become a new choice for non-small cell lung cancer chemotherapy drugs.
At the signing ceremony, Zhou Jinsong, chairman of Shanghai Yizhong, said: "Shanghai Yizhong is committed to developing a new generation of innovative drugs to provide patients with safe, effective and affordable high-quality drugs to meet the treatment needs that need to be solved urgently. Paclitaxel micellar is our first marketed product, and in the commercialization stage, we hope to cooperate with a professional third-party commercialization platform such as BAHEAL Pharmaceutical to jointly promote the entry of innovative drug products into the market and benefit more cancer patients. ”
Fu Gang, Chairman of BAHEAL Pharma, said: "As a third-party commercialization platform with brand operation as the core, BAHEAL Pharma has strict selection standards. The first is to choose products that can truly optimize clinical application scenarios, the second is to rely on professional evaluation capabilities to evaluate the technical barriers of products to avoid falling into a low-level duplication dilemma, and the third is to do a good job in element allocation with ecological collaboration, and select products that can truly complement and coordinate with BAHEAL resources for commercial operation. ”
"Paclitaxel micellar Zisheng is a third-generation paclitaxel with significant efficacy and good safety, and is a revolutionary product. BAHEAL Pharmaceutical will do a good job in the allocation of elements according to the characteristics of its life cycle, formulate reasonable commercialization solutions, and help products release value. Fu Gang further said. (Zhang Yang)
![Poinsettia partners ar882 global clinical Phase II .b trial patients enrolled[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)